760 These results together suggest that ACSL4 and LOX-catalyzed lipid peroxidation is involved in cerebral I/R injury, and inhibition of ACSL4 and LOX activity may be therapeutic targets for cerebral I/R injury
these effects were not noted in patients receiving the immediate-release product or extended-release capsules during clinical trials
This drug is currently approved to treat type-2 diabetes and reduce the risk of cardiovascular problems
The condition is defined as the presence of fat in more than 5% of liver cells (hepatocytes) on histology, or more than 5% liver fat content on MRI
"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet
FelizardoRWatanabeIDardiPRossoniLCmaraN